Effectiveness of Gabapentin for Treatment of Burning Mouth Syndrome

White, Theresa L.; Kent, Paul F.; Kurtz, D; Emko, Precha

doi:10.1001/archotol.130.6.786

Cited by 51 publications

(26 citation statements)

References 16 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The communication of different therapeutic measures to control the BMS is wide in the world literature (11)(12)(13)(14)(15)(16)(17)(18)(19)(20). The Gabapentin was used by White et al (15) in a case of a patient with BMS obtaining healing of the case and it was subsequently used by Heckmann et al (16) who conducted a study with gabapentin in 15 patients, where the initial dose was 300 mg / day and then grew at a rate of 300 mg every 48 hours to a maximum of 2400 mg / day.…”

Section: Discussionmentioning

confidence: 99%

“…The Gabapentin was used by White et al (15) in a case of a patient with BMS obtaining healing of the case and it was subsequently used by Heckmann et al (16) who conducted a study with gabapentin in 15 patients, where the initial dose was 300 mg / day and then grew at a rate of 300 mg every 48 hours to a maximum of 2400 mg / day. Seven of the patients were treated for two weeks, 6 patients for four weeks and another 2 patients for six weeks.…”

Section: Discussionmentioning

confidence: 99%

“…This drug was created to act as an agonist of the inhibitory neurotransmitter GABA of central activity since it is easily transferred to the central nervous system (CNS) for having high lipid solubility. The mechanism of action of this drug is still unknown because it acts by increasing the discharge promoted of GABA but without noting a steady reduce in the potentials of action or affection of the calcium channel current (15). The objective of this research was to test the action of alpha lipoic acid and gabapentin alone and jointly, on the symptoms of BMS.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: A randomized, double-blind, placebo controlled trial

López-D'alessandro¹,

Escovich²

2011

Med Oral

100

180

View full text Add to dashboard Cite

Burning Mouth Syndrome (BMS) is a disease that manifests as burning in the tongue or in any area of the oral mucosa, in the absence of clinically verifiable injuries. Objectives: To verify the efficacy of alpha lipoic acid (ALA) and gabapentin (GABA), used individually and jointly, to reduce the burning in patients with burning mouth and establish a drug therapy for the BMS. Study Design: During April and May 2008, we conducted a randomized, double-blind, placebo-controlled trial in the Department of Clinical Stomatology, Faculty of Dentistry, Rosario, Argentina. The gathering of patients was between those ones with BMS who were treated in our service between March 2003 and March 2008 without complying with the applied treatments. The 120 patients were randomly divided into 4 groups and were provided, by lot and in a blinded fashion, with four different treatment cycles consisting of the following drugs: Group A (n = 20) 600 mg / day of alpha lipoic acid for two months, Group B (n = 20) 300 mg / day of gabapentin for two months, Group C (n = 20) a combination of both drugs for two months and Group D (n = 60) 100 mg / day of cellulose starch for two months (control group). Results and Conclusions: All 120 patients completed the treatment. The best response was obtained with the combination of ALA + GABA, with a 70% of the cases with reduced burning in this group and a 13.2 times greater chance of presenting positive changes for these patients than those taking placebo. The combined use of drugs that act at different levels of the nociceptive system can be useful for the treatment of this syndrome.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: A randomized, double-blind, placebo controlled trial

López-D'alessandro¹,

Escovich²

2011

Med Oral

100

180

View full text Add to dashboard Cite

show abstract

“…However, the affinity of pregabalin for α 2 δ subunits is higher. Although both gabapentine and pregabalin were approved as first-choice drugs for neuropathic pain, there are few case reports on BMS responders to gabapentine 20,21 or pregabalin. 22 In particular, only 1 patient has been reported as responsive to the administration of pregablin at 50 mg/day.…”

Section: Discussionmentioning

confidence: 99%

Five Patients With Burning Mouth Syndrome in Whom an Antidepressant (Serotonin-Noradrenaline Reuptake Inhibitor) Was Not Effective, but Pregabalin Markedly Relieved Pain

Ito

Tokura²,

Yoshida³

et al. 2015

Clinical Neuropharmacology

View full text Add to dashboard Cite

Burning mouth syndrome (BMS) causes idiopathic pain or a burning sensation in clinically normal oral mucosa. Burning mouth syndrome is a chronic disease with an unknown etiology. Burning mouth syndrome is also idiopathic, and a consensus regarding diagnosis/treatment has not been reached yet. Recent studies have supported the suggestion that BMS is a neuropathic pain disorder in which both the peripheral and central nervous systems are involved. Tricyclic antidepressants (nortriptyline and amitriptyline), serotonin-noradrenaline reuptake inhibitors (SNRIs) (duloxetine and milnacipran), and antiepileptic drugs, potential-dependent calcium channel α2δ subunit ligands (gabapentine and pregabalin), are currently recommended as the first-choice drugs for neuropathic pain. In this study, we report 5 patients with BMS in whom there was no response to SNRI (milnacipran or duloxetine), or administration was discontinued because of adverse reactions, but in whom pregabalin therapy markedly reduced or led to the disappearance of pain in a short period. Pregabalin, whose mechanism of action differs from that of SNRIs, may become a treatment option for BMS patients who are not responsive to or are resistant to SNRIs.

show abstract

“…Gabapentin has demonstrated mixed results and studies are ongoing with pregabalin (White et al, 2004;Heckmann et al, 2006). Clonazepam reports and studies exhibit some promise (Gremeau-Richard et al, 2004).…”

Section: Managementmentioning

confidence: 99%

Burning Mouth Syndrome

Mock

Chugh

2010

Int J Oral Sci

View full text Add to dashboard Cite

Most clinicians dread seeing the patient presenting with a primary complaint of a burning pain on one or more oral mucosal surfaces. Unlike most other clinical conditions presenting in a dental office, burning mouth syndrome is poorly understood with few evidence based remedies. More recently, advances have been made towards clarifying the possible etiology of the disorder and testing the possible therapeutic modalities available. This article attempts to summarize the "state of the art" today.

show abstract

Effectiveness of Gabapentin for Treatment of Burning Mouth Syndrome

Cited by 51 publications

References 16 publications

Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: A randomized, double-blind, placebo controlled trial

Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: A randomized, double-blind, placebo controlled trial

Five Patients With Burning Mouth Syndrome in Whom an Antidepressant (Serotonin-Noradrenaline Reuptake Inhibitor) Was Not Effective, but Pregabalin Markedly Relieved Pain

Burning Mouth Syndrome

Contact Info

Product

Resources

About